← All trials
NCT04969250
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 25, 2021
- Primary completion
- Jul 31, 2022
- Completion date
- Jul 31, 2022
- First posted
- Jul 20, 2021
- Last posted
- Nov 26, 2021
- Enrollment
- 640
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)Lead sponsor
- Department of Veteran AffairsCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- University of New South WalesCollaborator
- University of CopenhagenCollaborator
- Medical Research CouncilCollaborator
- AIDS Clinical Trials GroupCollaborator
- Department of Veteran AffairsCollaborator
- University of MinnesotaCollaborator
- University of CopenhagenOverall official - principal investigator
- Cardiothoracic Surgical Trials NetworkCollaborator
- Prevention and Early Treatment of Acute Lung Injury (PETAL)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.